Successful delayed thrombolytic therapy in a patient with massive pulmonary embolism

Journal of the Formosan Medical Association

Volumn 97, Issue 9, 1998, Pages 638-641

  Chao, Ting Hsing ^a   Tsai, Liang Miin ^a   Teng, Jeng Kai ^a   Li, Yi Heng ^a   Tsai, Wei Chuan ^a   Lin, Li Jen ^a   Chen, Jyh Hong ^a  

^a NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Pulmonary embolism; Thrombolytic therapy

Indexed keywords

ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CASE REPORT; CAUSE OF DEATH; DIAGNOSTIC IMAGING; FEMALE; FIBRINOLYTIC THERAPY; FOLLOW UP; HUMAN; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG PERFUSION; RECURRENT DISEASE;

FEMALE; HUMANS; MIDDLE AGED; PULMONARY EMBOLISM; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 0031720361     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Goldhaber SZ: Contemporary pulmonary embolism thrombolysis. Chest 1995;107(Suppl):45S-51S.
2. Daniels LB, Parker JA, Patel SR, et al: Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997; 80:184-8.
3. Dalla-volta S, Palla A, Santolicandro A, et al: PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. J Am Coll Cardiol 1992;20:520-6.
4. Goldhaber SZ, Haire WD, Feldstein ML, et al: Alteplase versusheparin in acute pulmonary embolism, randomized trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-11.
5. Levine M, Hirsh J, Weitz J, et al: A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9.
6. Dalen JE, Alpert JS: Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:257-70.
7. More RS, Chauhan A: Pulmonary embolism - the role of thrombolytic therapy in its management. Postgrad Med J 1996;72:157-61.
8. Lualdi JC, Goldhaber SZ: Right ventricular dysfunction after acute pulmonary embolism: pathophysiologic factors, detection, and therapeutic implications. Am Heart J 1995;130:1276-82.
9. Hall RJC, Sutton GC, Kerr IH: Long-term prognosis of treated acute massive pulmonary embolism. Br Heart J 1977;39:1128-34.
10. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia M de L, et al: Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized con trolled trial. J Thromb Thrombolys 1995;2:227-9.
11. Konstantinides S, Geilbel A, Olschewski M, et al: Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997;96:882-8.
12. Goldhaber SZ, Vaughan DE, Markis JE, et al: Acute pulmonary embolism treated with tissue plasminogen activator. Lancet 1986;2:886-8.
13. Meyer G, Sors H, Charbonnier B, et al: Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992;19:239-45.
14. Verstraete M, Miller GA, Bounameaux H, et al: Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute pulmonary embolism Circulation 1988;77:353-60.
15. Come PC, Kim D, Parker JA, et al: Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987;10:971-8.
16. Parker JA, Markis JE, Palla A, et al: Pulmonary perfusion after rt-PA therapy for acute embolism: early improvement assessed with segmental perfusion scanning. Radiology 1988;166:441-5.